OG-L002 is primarily utilized in research settings as a potent and selective inhibitor of LSD1 (lysine-specific demethylase 1), an enzyme involved in the regulation of gene expression. Its application is significant in the study of epigenetic mechanisms, particularly in cancer research, where LSD1 inhibition is explored as a potential therapeutic strategy. By blocking LSD1, OG-L002 can modulate the expression of genes associated with tumor growth and progression, making it a valuable tool for understanding and targeting epigenetic changes in various cancers, including leukemia and breast cancer. Additionally, it is used in biochemical assays to investigate the role of LSD1 in stem cell differentiation and cellular reprogramming, contributing to advancements in regenerative medicine and developmental biology.